Cosyntropin (Cortrosyn)
Overview
A synthetic peptide consisting of the first 24 amino acids of the 39-amino acid adrenocorticotropic hormone (ACTH). Cosyntropin retains full biological activity of native ACTH for stimulating adrenal cortisol production and is used as a diagnostic agent in the ACTH stimulation test to evaluate adrenal gland function. It binds to the MC2R receptor on adrenocortical cells, activating steroidogenesis.
Key Research Findings
FDA-approved as a diagnostic agent for adrenal insufficiency. The standard-dose (250 mcg) and low-dose (1 mcg) ACTH stimulation tests are cornerstones of adrenal function assessment. A cortisol response below 18-20 mcg/dL at 30-60 minutes post-injection indicates adrenal insufficiency. Widely used in endocrinology with an excellent safety profile.
Intravenous, Intramuscular injection
FDA Approved
Interested in Cosyntropin (Cortrosyn)?
Find a verified provider experienced with Cosyntropin (Cortrosyn) protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Cosyntropin (Cortrosyn) ProviderRelated Peptides
CJC-1295
In Clinical TrialsA synthetic analog of growth hormone-releasing hormone (GHRH) with a Drug Affinity Complex (DAC) that binds to albumin, extending its half-life from minutes to approximately 6-8 days. CJC-1295 stimulates pulsatile GH release from the anterior pituitary by binding to GHRH receptors while preserving the natural GH secretory pattern and negative feedback mechanisms.
Ipamorelin
In Clinical TrialsA highly selective growth hormone secretagogue that acts on ghrelin/GHS receptors in the pituitary gland to stimulate GH release. Unlike other GH secretagogues, ipamorelin does not significantly affect ACTH, cortisol, or prolactin levels, making it one of the most specific GH-releasing peptides. It works synergistically with GHRH analogs like CJC-1295.
Sermorelin
FDA ApprovedA synthetic 29-amino acid analog of GHRH representing the shortest fully functional fragment of the native 44-amino acid hormone. Sermorelin stimulates the pituitary to produce and release growth hormone through the natural GHRH receptor pathway, preserving the hypothalamic-pituitary feedback axis. It maintains physiological pulsatile GH secretion patterns.
Tesamorelin (Egrifta)
FDA ApprovedA synthetic GHRH analog consisting of the 44-amino acid sequence of human GHRH with a trans-3-hexenoic acid modification at the N-terminus to improve stability. Tesamorelin specifically targets visceral adipose tissue reduction by stimulating lipolysis through GH-mediated pathways. It is the only FDA-approved treatment for HIV-associated lipodystrophy.